Avaliação de tuberculose infecção em pacientes com artrites inflamatórias crônicas: dados do registro PANLAR de doenças reumáticas (PANRED)
Loading...
Date
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Universidade Federal de Juiz de Fora (UFJF)
Abstract
Tuberculosis disease (TBD) is a global public health issue, and its latent form, or
tuberculosis infection (TBI), affects approximately one-quarter of the world’s
population. TBI is a non-pathological state in which viable forms of Mycobacterium
tuberculosis exist within the host but are contained by the immune response. Patients
with immune-mediated rheumatic diseases are at risk of TBI reactivation, especially
when using tumor necrosis factor (TNF) inhibitors. Different safety profiles related to
TBI exist among the various disease-modifying antirheumatic drugs (DMARDs),
including targeted synthetic DMARDs (tsDMARDs), conventional synthetic DMARDs
(csDMARDs), and biological DMARDs (bDMARDs). The objective of the present
study was to evaluate the diagnosis and treatment of TBI at the initiation of
immunosuppressive therapy and during 12 months of follow-up in patients with
chronic inflammatory arthritis (CIA) using different types of DMARDs, as well as the
screening methods for TBI and the occurrence of TBD. This was an observational,
prospective, multicenter, real-world study that included patients classified as having
rheumatoid arthritis (RA), psoriatic arthritis, and axial spondyloarthritis from the PanAmerican League of Rheumatology Associations (PANLAR) Registry of Rheumatic
Diseases (PANRED). TBI data from 590 patients were analyzed, with a 12-month
follow-up after starting DMARD therapy, from rheumatology centers in Brazil,
Argentina, Uruguay, Peru, and Paraguay. Descriptive statistics were used to
summarize patient characteristics. Among the participants, 460 (78%) were women,
with a mean age of 52.4±12.9 years; 279 (47.9%) were mestizos, 496 (84.1%) had
RA, 321 (54.4%) were using glucocorticoids (GCs), 262 (44.4%) were on bDMARDs
(mainly TNF inhibitors), 169 (28.6%) on tsDMARDs and 159 (26.9%) on csDMARDs,
respectively. TBI screening was performed in 430 (72.9%) individuals at baseline.
Fifty-nine patients (13.7%) were diagnosed with TBI at baseline. The screening
methods used were: tuberculin skin test in 389 (90.5%); interferon-gamma release
assay (IGRA) in 60 (13.9%); imaging (X-ray or chest computed tomography) in 211
(49.1%); and history of recent contact with TBD pulmonary or laryngeal in 205
(47.7%) patients. After 12 months, 99 (23%) patients underwent repeat screening,
with 5 (5.0%) new cases of TBI. Two patients (0.34%) developed TBD: one using
tocilizumab and GCs (5 mg/day) and another using rituximab in addition to
csDMARDs. Screening and treatment of TBI were performed in most patients with
CIA at the start of immunosuppressive therapy. However, a significant portion of
individuals remained unscreened, highlighting the need for greater attention from
attending rheumatologists in this context, with the aim of reducing the risk of TBD
and its associated morbidity and mortality.
Description
Citation
Collections
Endorsement
Review
Supplemented By
Referenced By
Creative Commons license
Except where otherwise noted, this item's license is described as Acesso Aberto

